Glyxambi is a combination medication containing empagliflozin 10 mg and linagliptin 5 mg [1]. It is prescribed to help control blood sugar levels in adults with type 2 diabetes mellitus [1].
What is Glyxambi used for?
Glyxambi is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes [1]. It is typically prescribed when a patient's blood sugar is not adequately managed by other treatments.
How does Glyxambi work?
Glyxambi combines two different mechanisms of action to lower blood sugar. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor, which works by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be eliminated in the urine [1]. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing levels of incretin hormones. These hormones help to increase insulin release and decrease glucagon secretion from the pancreas, thereby reducing glucose production by the liver [1].
What are the benefits of Glyxambi?
By targeting different pathways, Glyxambi offers a dual approach to blood sugar management. Studies have shown that combination therapies like Glyxambi can be more effective at lowering HbA1c levels compared to monotherapy [2]. Additionally, empagliflozin, one of the components of Glyxambi, has demonstrated cardiovascular benefits and a reduction in the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease [3].
Who makes Glyxambi?
Glyxambi is manufactured by Boehringer Ingelheim [1].
What are the potential side effects of Glyxambi?
Common side effects of Glyxambi can include nasopharyngitis (common cold), diarrhea, and cough [1]. More serious, though less common, side effects may include pancreatitis, hypersensitivity reactions, and hypoglycemia (low blood sugar), especially when used with a sulfonylurea or insulin [1].
When does Glyxambi patent expire?
Information on the specific patent expiry dates for Glyxambi can be found on specialized patent tracking websites [4]. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and their expiry dates, which can influence the availability of generic versions of medications [4].
Can generic versions of Glyxambi be made?
The availability of generic versions of Glyxambi is dependent on the expiry of its patents. Once patents expire and regulatory hurdles are cleared, other companies may be able to manufacture and market generic versions of the drug [4].
How does Glyxambi compare to other diabetes medications?
Glyxambi offers a combination therapy that targets both glucose excretion (empagliflozin) and incretin pathways (linagliptin). This contrasts with medications that focus on a single mechanism, such as metformin (which reduces glucose production and improves insulin sensitivity) or other SGLT2 inhibitors or DPP-4 inhibitors used alone. The choice of medication depends on individual patient needs, comorbidities, and treatment goals. For instance, empagliflozin's established cardiovascular benefits may make Glyxambi a consideration for patients with type 2 diabetes and existing cardiovascular disease [3].
What is the typical dosage for Glyxambi?
The recommended starting dose of Glyxambi is one tablet taken orally once daily [1]. The tablet contains empagliflozin 10 mg and linagliptin 5 mg. Doses can be adjusted by a healthcare provider based on the patient's response and tolerance [1].
Are there any contraindications for Glyxambi?
Glyxambi is contraindicated in patients with known serious hypersensitivity to linagliptin or empagliflozin, or to any of the excipients in the tablet [1]. It is also not recommended for patients with a history of pancreatitis [1].
---
Sources:
[1] https://www.glyxambi.com/
[2] https://pubmed.ncbi.nlm.nih.gov/24650098/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1504730
[4] https://drugpatentwatch.com/